Quarterly results

• 2012 Fourth Quarter - released 06 February 2013

  Released 06 February 2013

  Simon Dingemans, CFO, and Sir Andrew Witty, CEO, discuss our fourth quarter results 2012.

   

  • View the press release

  

  Key highlights

  • Core EPS of 112.7p and returns of £6.3bn to shareholders
  • 2012 dividend of 74p (+6%)
  • Group sales -1%; flat excluding disposals of OTC brands
  • Successful R&D delivery: six new drugs filed since start of 2012

  Related downloads

  • Q4 2012 results announcement PDF - 286.3KB
  • Q4 2012 results analyst presentation colour PDF - 408.1KB
  • Q4 2012 analyst presentation bandw PDF - 351.1KB
  • Q4 2012 analyst presentation transcript PDF - 68.1KB
  • Q4 2012 actual growth schedules PDF - 35.3KB
  • Q4 2012 US dollar translation PDF - 31.8KB

• 2012 Third Quarter - released 31 October 2012

  Released 31 October 2012

  Simon Dingemans, CFO, discusses our Q3 results 2012.

  

  Key highlights

  • Core EPS of 26.5p
  • Dividend of 18p (+ 6%)
  • Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
  • Continued strong cash generation and returns to shareholders

  Related downloads

  • Q3 2012 results announcement PDF - 293.8KB
  • Q3 2012 actual growth schedules PDF - 32.2KB
  • Q3 2012 US dollar translation PDF - 31.2KB

• 2012 Second Quarter - released 25 July 2012

  Released 25 July 2012

  Watch Sir Andrew Witty, CEO, discuss our second quarter results 2012.

  • View the press release

  

  Key highlights

  • Core EPS of 26.4p
  • Dividend of 17p (up 6%)
  • Significant late-stage pipeline delivery

  Related downloads

  • Q2 2012 results announcement PDF - 301.0KB
  • Q2 2012 analyst presentation PDF - 2.2MB
  • Q2 2012 analyst presentation (printable version) PDF - 1.0MB
  • Q2 2012 actual growth schedules PDF - 37.0KB
  • Q2 2012 US dollar translation PDF - 32.8KB

• 2012 First Quarter - released 25 April 2012

  Released 25 April 2012

  Watch Simon Dingemans, CFO, discuss our first quarter results 2012.

  

  Key highlights

  • Sales growth of +2% CER
  • Further R&D delivery, operational leverage and continued returns to shareholders
  • Core EPS 27.3p (+7%), dividend up 6% to 17p

  Related downloads

  • Q1 2012 results announcement PDF - 258.7KB
  • Q1 2012 Simon Dingemans transcript PDF - 35.5KB
  • Q1 2012 actual growth schedules PDF - 22.5KB
  • Q1 2012 US dollar translation PDF - 24.9KB